Results 151 to 160 of about 5,082,017 (204)

Antibody dependent complement activation is critical for boosting opsonophagocytosis of Staphylococcus epidermidis in an extremely preterm human whole blood model. [PDF]

Sci Rep
Beudeker CR, van Dalen R, Ruyken M, de Haas CJC, Scheepmaker LM, Vijlbrief D, Lely AT, van Kessel KPM, van der Bruggen JT, Rooijakkers SHM, Salazar LA, van der Flier M.   +11 more
europepmc   +1 more source

Comparative genomics of three non-hematophagous leeches (<i>Whitmania</i> spp.) with emphasis on antithrombotic biomolecules. [PDF]

Front Genet
Zhao F, Huang Z, Tang L, Zhang W, Liu Z, Lin G.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Monitoring of hirudin therapy with the thrombelastograph®

Journal of Clinical Anesthesia, 2002
Lepirudin is a specific thrombin inhibitor that is used for anticoagulation in patients with heparin-induced thrombocytopenia who are also undergoing cardiopulmonary bypass (CPB). Monitoring of lepirudin during CPB has been carried out with activated clotting time and ecarin clotting time.
E. Pivalizza
openaire   +3 more sources

Hirudin therapy during thrombolysis for venous thrombosis in heparin-induced thrombocytopenia

Vascular Medicine, 2000
Heparin-induced thrombocytopenia (HIT) is the most common drug-related thrombocytopenia. Thromboembolic complications occur in approximately 50% of patients with HIT and result in limb amputation and death in up to 20% and 30% respectively. Because patients with a history of HIT may require future intravenous anticoagulation but have a high-risk of ...
M P, Reilly, R, Weiss, A, Askenase, C, Tuite, M, Soulen, E R, Mohler   +5 more
openaire   +3 more sources

Hirudin versus heparin for anticoagulation in continuous renal replacement therapy

Intensive Care Medicine, 2001
To compare the efficacy and safety of hirudin and heparin for anticoagulation during continuous renal replacement therapy (CRRT) in critically ill patients.Prospective, randomized controlled pilot study.Single centre; interdisciplinary intensive care unit at a university hospital.Seventeen patients receiving CRRT.Patients were randomly allocated to two
Hein OV, von Heymann C, Lipps M, Ziemer S, Ronco C, Neumayer HH, Morgera S, Welte M, Kox WJ, Spies C   +9 more
openaire   +4 more sources

[Effects of combined natural hirudin and hyperbaric oxygen therapy on survival of transplanted random-pattern skin flap in rats].

Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 2018
To investigate the effect of natural hirudin combined with hyperbaric oxygen therapy on the survival of transplanted random-pattern skin flap in rats.A random-pattern skin flap in size of 10.0 cm×2.5 cm was elevated on the dorsum of 72 Sprague Dawley rats. Then the 72 rats were randomly divided into 4 groups ( n=18) according to the therapy method.
Jieyun, Cai, Bojie, Lin, Xinyuan, Pan, Jia, Cui, Rohan, Pradhan, Guoqian, Yin   +5 more
openaire   +3 more sources

Hirudin and Hirulog: Advances in antithrombotic therapy

Perspectives in Drug Discovery and Design, 1994
Over the past two decades, advances in the prevention and treatment of coronary artery disease, e.g., coronary angioplasty and coronary thrombolysis, have been coupled with the need for improved antithrombotic therapy to prevent acute, life-threatening thrombotic complications.
J. Maraganore
openaire   +2 more sources

Therapy and Monitoring of Heparin-Induced Thrombocytopenia Type II in Critically Ill Patients During Continuous Venovenous Hemodiafiltration: Comparison of aPTT and Ecarin Clotting Time for Monitoring of r-Hirudin Therapy

Journal of Intensive Care Medicine, 2002
We conducted a survey of therapy, complications, and monitoring of heparin-induced thrombocytopenia (HIT) type II in critically ill patients during continuous venovenous hemodiafiltration (CVVHDF). We also compared activated partial thromboplastin time (aPTT) and ecarin clotting time (ECT) for monitoring recombinant (r)-hirudin therapy.
Elke Muhl, Hans-Joachim Siemens, Peter Kujath, Hans-Peter Bruch   +3 more
openaire   +2 more sources

Monitoring Anticoagulant Therapy by Activated Partial Thromboplastin Time: Hirudin Assessment

Thrombosis and Haemostasis, 1994
SummaryBackground. Recombinant hirudin (RH) is a new anticoagulant for prophylaxis and treatment of venous and arterial thrombosis. To which extent the activated partial thromboplastin time (APTT) is suitable for monitoring of RH has not been properly evaluated.
Nurmohamed, M T, Berckmans, R J, Morriën-Salomons, W M, Berends, F, Hommes, D W, Rijnierse, J J, Sturk, A   +6 more
openaire   +6 more sources

Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. II. Adjunctive Therapy with r-Hirudin

Journal of Cardiovascular Pharmacology, 1994
We examined the effectiveness of the direct-acting thrombin inhibitor, recombinant hirudin (r-hirudin), for prevention of coronary rethrombosis after thrombolysis with recombinant tissue plasminogen activator (rt-PA) in a canine model of coronary artery thrombosis.
W E, Rote, D X, Mu, E R, Bates, M A, Nedelman, B R, Lucchesi   +4 more
openaire   +3 more sources